The Latest Breaking News from Abbott Labs

These companies offer stability and a history of dividend growth. Are they right for you?

Abbott stock edged higher Wednesday after the health care giant narrowly beat Wall Street's third-quarter expectations.

June S&P 500 futures (ESM23) are down -0.46%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.76% this morning after three major U.S. benchmark indices struggled for direction on Tuesday as investors weighed the latest batch of earnings reports and comments from two Federal Reserve officials.

June S&P 500 futures (ESM23) are down -0.46%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.76% this morning after three major U.S. benchmark indices struggled for direction on Tuesday as investors weighed the latest batch of earnings reports and comments from two Federal Reserve officials.

The Dow Jones dropped 300 points Wednesday, as Boeing and Microsoft fell on earnings. Tesla earnings are due after the close.

Leading healthcare company Abbott Laboratories (ABT) reported strong second-quarter results. And given the company is well-positioned to capitalize on its diverse business and recent FDA approvals, is it wise to buy the stock now? Let’s find out.

Shortages of vital, life-preserving goods are routine in America – and they’re the product of bad policy

WASHINGTON — President Joe Biden defended his administration’s response to a national baby formula shortage, saying he acted as soon he became aware of the crisis in April — even as manufacturers told him Wednesday they saw it coming months earlier.

Abbott stock climbed Wednesday as it reported quarterly results that beat estimates, driven by $3.3 billion in sales of its Covid-19 tests.